DNA Vaccine for Zika (GLS-5700)

HOME > Products > DNA Vaccine for Zika
(GLS-5700)
R&D history

Q4 2015, Started work on the development of Zika virus DNA vaccine

- Generation of DNA vaccine constructs targeting multiple Zika virus antigens
- Synthetic consensus sequence based on pre-2016 isolates

Feb 2016, Reported successful results of preclinical studies on Zika DNA vaccine

- Mouse study : All vaccinated mice showed evidence of seroconversion as well as robust
                     and broad T-cell response.
- Immunogenicity assessment in larger animals (including rabbits, guinea pigs, and monkeys) is underway.

May 2016, Completed drug product manufacture of Zika vaccine for clinical trial

Jun 2016, Received approval for first clinical trial evaluating Zika vaccine in humans

Zika Virus Particle